Status of methylation of MGMT promoter resulted to be a significant prognostic factor for OS. Radiotherapy-related acute toxicity was not relevant. Three patients (12.5%) had G3 myelotoxicity that required temozolomide temporary interruption or dose reduction during the chemotherapy. However, chemotherapy was not definitely discontinued for toxicity in any case. One patient out of 24 (4.2%) developed radionecrosis that required surgical resection with no evidence of disease in the surgical specimen. Conclusions This trial confirms that hypofractionated radiotherapy with SIB and association with temozolomide may be a reasonable and feasible option for good prognosis patients with GBM.
Introduction
The standard therapy for glioblastoma is maximal safe surgery followed by conventionally fractionated radiotherapy to a total dose of 60 Gy plus concomitant and sequential temozolomide, as a phase III trial by European Organization for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada (NCIC) showed an improved overall and progression-free survival compared to patients treated with exclusive postoperative radiotherapy [1] .
Several studies reported about hypofractionated treatments in high grade gliomas with negative prognostic factors, obtaining good results in terms of efficacy and toxicity [2] [3] [4] [5] . Hypofractionated radiotherapy might be an option also for good prognosis patients considering that a shorter duration of the treatment leads to advantages from a quality of life's perspective for the patients and cost savings in terms of machine time [4] .
Moreover, intensity modulated radiotherapy (IMRT) provides the chance to administer a simultaneous integrated boost (SIB), using different doses per fraction in different areas of the target.
The current multicentric phase II study was proposed by the Brain Working Group of the Italian Association of Radiation Oncology (AIRO). The study aimed at evaluating the efficacy in terms of overall survival (OS) and progression-free survival (PFS) and toxicity of a hypofractionated schedule with SIB in association with concomitant and sequential temozolomide (TMZ) in patients with relatively good prognosis (RPA classes III and IV [6] ).
This trial was opened on September 2009 and, then, it was closed early on November 2014, due to poor accrual.
Methods

Study design
This multicentre trial was undertaken in nine radiotherapy departments in Italy.
Patients were eligible for inclusion in the trial if they were newly diagnosed with histologically proven glioblastoma; were at least 18 years of age; belonged to Recursive Partitioning Analysis (RPA) class III (age < 50, KPS 90-100) or IV (age < 50, KPS < 90; age ≥ 50, surgical resection, good neurologic function); had preoperative MRI scan showing a lesion with maximum diameter ≤4 cm in contrast-enhanced T1-weighted sequences; had availability of postoperative MRI scan; had adequate bone marrow, renal, and liver function; agreed to use effective contraception if women of childbearing potential.
Exclusion criteria were lesions sited in the brainstem or infiltrating the spinal cord, previous radiation treatment to the brain, previous malignancies except for carcinoma in situ of the cervix or basal cell carcinoma, pregnant or lactating woman, and psychiatric disturbances.
Local institutional review board of each participating institution approved the study protocol.
Database development, central data management, statistical analysis, safety management and trial management were done at the Department of Radiation Oncology in Florence.
All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
The primary aim of the study was the evaluation of actuarial OS at 12 months (12-month OS). The study was designed to detect an advantage in terms of survival at 12 months from 0.61, (12-month OS reported for patients enrolled in the EORTC/NCIC trial [1] ), to 0.78 with statistical power at 80% and alpha = 0.05. The sample size needed was estimated to be 66 patients.
Survival rates were calculated according to Kaplan-Meier analysis, starting from the day of surgery to the day of last follow-up or death for OS and to the day of evidence of radiological progression or to the day of last follow-up for PFS.
Univariate and multivariate analysis were conducted with the main prognostic factors using Log-rank test and Cox regression model, respectively, for assessing the prognostic value of different factors in terms of OS and PFS. The following prognostic factors were evaluated: gender, age (≤65 vs >65), preoperative KPS (≤80 vs >80) and postoperative KPS (≤80 vs >80), extent of surgery (gross total resection vs subtotal resection vs biopsy), maximum diameter of preoperative gross tumor (≤3 vs >3 cm), and O6-methylguanin-DNA-methyltransferase (MGMT) promoter methylation status (methylated vs not methylated).
Radiotherapy
Patients were immobilized with an individualized thermoplastic mask or with other devices with <3 mm of uncertainty.
Slice thickness of the simulation computed tomography (CT) was ≤3 mm. Co-registration with postoperative MRI was mandatory.
The gross tumor volume (GTV) was defined on contrastenhanced T1-weighted sequences and it included the operative bed and any residual contrast enhanced lesion.
The clinical target volume for the SIB (CTV67.5 Gy) was defined as the GTV + 5 mm margin, whereas the clinical target volume for the lower-dose volume (CTV52.5 Gy) was obtained by adding a 10 mm margin to the CTV67.5 Gy.
Modifying the CTV volumes was recommended in case of proximity to anatomical barriers such as dura, tentorium, ventricles, and falx cerebri.
Both the PTV67.5 Gy and PTV52.5 Gy were defined by expanding the corresponding CTV of a 3-mm margin.
The dose prescription was the following: 52.5 Gy in 15 fractions of 3.5 Gy each and 67.5 Gy in 15 fractions of 4.5 Gy each for the SIB. Considering an alpha/beta ratio equal to 10 for glioblastoma, the biologically effective dose (BED) of this schedule was equal to 97.8 Gy for the SIB and to 70.8 Gy for the lower-dose volume.
Such a schedule was defined considering the data published by Iuchi et al. [7] who found that BED ≥ 96 Gy in the boost volume was related to better outcomes in terms of both local control and overall survival.
Furthermore, a schedule for the lower-dose volume corresponding to a BED equal to 70.8 Gy was chosen in order to prescribe a dose similar to that commonly administered during the standard treatment. It is in fact noteworthy that the standard treatment consisting in 60 Gy in 30 fractions corresponds to a BED of 72 Gy for an alpha/beta ratio of 10 Gy.
Prescription was defined following the ICRU 50 and ICRU 62 guidelines [8, 9] . For the boost volume, the coverage was considered optimal when the 95% of the prescribed dose (i.e. 64.1 Gy) was delivered to 100% of the PTV67.5 Gy, while keeping the volume receiving 107% of the prescribed dose (i.e. 72.2 Gy) below 10% of the PTV67.5 Gy.
For the lower-dose volume, the prescription was given to the ring structure obtained by subtracting PTV67.5 Gy from PTV52.5 Gy. For this volume, optimal coverage was defined as delivering 95% of prescribed dose (i.e. 49.9 Gy) to 100% of PTV52.5 Gy, without exceeding 72.2 Gy (i.e. 107% of the prescribed dose for the boost volume) to more than 1% of the PTV52.5 Gy.
Contouring of the following organs at risk (OARs) was required: ocular globes, lenses, optic nerves, optic chiasm, brainstem, spinal cord, brain, pituitary gland and cochleae.
Estimation of dose constraints for the hypofractionation schedule with dose per fraction of 4.5 Gy was based on the linear quadratic model for each OAR (Table 1) . Different priorities for each region of interest (ROI) were suggested for the inverse planning.
Secondary dose constraints criteria were proposed both for OARs and target volumes in case of critical location and extent of PTV.
Treatment was performed with IMRT or other highly conformal techniques allowing meeting the critical organs constraints. Energy of photon beam was ≥6MV.
Calculation grid size was ≤2 mm. Patient based pre-treatment verification was conducted for all the IMRT plans, following the quality assurance procedures established at each center. Radiotherapy was started within 6 weeks from surgery and it was performed in 15 daily fractions, 5 days a week; thus, the treatment duration was 3 weeks (Fig. 1) .
Patient positioning verification was achieved through matching of digitally reconstructed radiographies (DRRs) with portal images, or through on board kilovoltage or megavoltage cone beam CT images. Verification was performed at least for the first three fractions and, then, on a weekly basis.
Chemotherapy
Radiotherapy was associated with concomitant chemotherapy with temozolomide (TMZ) 75 mg/m 2 /day, 7 days/ week, from the first day until the end of radiotherapy. Blood count was monitored throughout treatment weekly or more frequently, if needed.
Four weeks after completing the concomitant phase, chemotherapy with TMZ was administered for additional 6 cycles of maintenance treatment. Dosage in the first cycle was 150 mg/m 2 once daily for 5 days. Starting from the second cycle, the dose was escalated to 200 mg/m 2 in the absence of toxicity.
TMZ was administered daily, in the morning, on an empty stomach, preferably 1 h before radiation treatment. Metoclopramide or serotonin antagonists were used to control nausea and vomiting associated with the administration of TMZ.
Each institution could decide to continue TMZ besides 6 cycles in case of controlled disease and good tolerance to the chemotherapy.
Toxicity assessment
Side effects of radiotherapy were evaluated according to Radiation Therapy Oncology Group (RTOG) scale [18] .
Acute toxicity of chemotherapy was assessed according to Common Terminology Criteria for Adverse Events v4.0 (CTCAE) [19] .
Chemotherapy was continued throughout the concomitant period if all of the following conditions were met: absolute neutrophilic count ≥1.5 × 109/L, platelet count ≥100 × 109/L, common toxicity criteria (CTC) non-hematological toxicity less than or equal to grade 1 (except for alopecia, nausea and vomiting).
During the sequential treatment a complete blood count was obtained 21 days after the first dose. The next cycle of TMZ was not started until the ANC was above 1.5 × 109/L (1500/μL) and the platelet count exceeded 100 × 109/L.
The dose of chemotherapy with TMZ was reduced according to the criteria listed in the drug prescribing information.
Whenever radionecrosis was detected, it was classified according to CTCAE version 4.0 [19] . Treatment-related chronic toxicity was scored according to RTOG/EORTC scale for late toxicity [18] .
Follow-up
Patients were followed with clinical assessment and MRI scans after 3 and 6 chemotherapy cycles, and, thereafter, every 3 months (or earlier if clinically indicated).
Progressive disease was defined as a 25% increase in the size of one or more measurable lesions or the appearance of new lesions [20] .
In case of clinical worsening before the first planned response assessment, the MRI scan was moved up. In case of apparent progression within 3 months from the end of concomitant treatment, the patient underwent spectroscopy and/or perfusion MRI to differentiate pseudo-progression from relapsing tumor. In case of lack of evidence of progressive disease, patients continued temozolomide until the following evaluation.
In case of progression, patients received salvage chemotherapy or best supportive care.
For each patient, day of last follow-up, day of evidence of progression disease and day of death were recorded.
Results
Efficacy
Between September 2009 and November 2014, 24 patients were enrolled. The baseline clinical characteristics are listed in Table 2 .
Ten patients had a maximum tumor size in the preoperative contrast-enhanced T1 weighted imaging of ≤3 cm. PTV67.5 Gy volume was ≤100 cc in 17 cases; PTV52.5 Gy was ≤150 cc in 15 patients.
Median OS was 15.1 months, actuarial OS at 12 months was 65.6% ± 0.09, whereas actuarial OS at 36 months was 10.1% ± 0.07 (Fig. 2a) .
Median PFS was 8.6 months, actuarial PFS at 12 months was 41.2% ± 0.10 (Fig. 2b) .
Univariate analysis showed that methylation status of the promoter of MGMT was a significant prognostic factor for OS. The significance of MGMT was borderline (p = 0.07) at the multivariate analysis. All the other parameters (gender, age, preoperative and postoperative KPS, extent of surgery, maximum diameter, PTV volume) were not significantly related to OS.
No prognostic factor resulted to have an impact on PFS.
Toxicity
Radiotherapy-related acute toxicity was no relevant. There were four chemotherapy interruptions (16.6%) during the concomitant phase, all lasted ≤5 days: 2 patients had an interruption for myelosuppression (n = 1 G2 thrombocytopenia and n = 1 G2 neutropenia), one for G2 fatigue and another one for G2 impairment of liver function. Six out of 24 patients required an increasing dose of antiedemigen drugs during RT for worsening of neurological symptoms. A case of G3 neutropenia and 2 cases of G3 thrombocytopenia occurred during the chemotherapy maintenance phase and caused a dose reduction for the following cycles. There was no case of TMZ definitive discontinuation due to toxicity. Two patients did not receive sequential TMZ at all because of severe clinical progression and lack of evidence of pseudo-progression at perfusion and spectroscopy MRI. They both died within 6 months from the end of the treatment for progressive disease. Among patients who had maintenance TMZ, 3 had more than 6 cycles.
All the radiotherapy plans met the dose constraints for the organs at risk defined for the hypofractionated schedule. During the long-term follow-up, there was no toxicity to the organs at risk for which constraints had been set, except for a case of G4 radionecrosis of the brain parenchyma: the patient required to be operated and there was no evidence of disease in his pathology specimen.
Discussion
Rationale
From a radiobiological point of view, hypofractionation may lead to increased cell killing and reduction of tumor repopulation [21] [22] [23] . Remarkably, the reduction of overall treatment time in hypofractionated regimens may represent a significant benefit in terms of quality of life for patients with such a severe prognosis [24] [25] [26] . The introduction in the clinical practice of IMRT is related to a better conformity in dose release with advantages in terms of potential treatment-related toxicity [22] . Another benefit of IMRT is the possibility of administering a SIB with differentiated doses within the target volume [17] .
Literature analysis
There are several studies reporting the use of IMRT with SIB in high grade gliomas (Table 3 ). The interpretation of the findings in literature is not easy because the existing studies included a limited number of patients and some series included also WHO grade III gliomas, introducing an important bias for understanding the efficacy of the treatment. Importantly, the interpretation of the results in terms of outcome is limited by significant heterogeneities in the definition of the target and in the employed radiation schedules.
Target definition
The definition of target volumes varied very widely both for the lower-dose volume and for the boost volume. For the lower-dose volume, some authors included the peritumoral edema [7, 22, 32] or even the peritumoral edema with the addition of heterogeneous anisotropic margin [28, 29] , while others chose as CTV for the lower-dose volume an isotropic expansion of the gross tumor volume ranging from 1.5 [23, 27 ] to 2 cm [30, 33, 34] . For the SIB volume, most authors chose to administer the boost on the GTV, defined as surgical cavity plus any enhancing lesion [22, 23, 27, 28, 30, 32, 33] , while others prescribed the boost dose to an isotropic expansion of GTV ranging from 0.5 cm [7] to 1 cm [29] . Only in the series published by Nakamatsu et al. [34] , the definition of GTV was based on the preoperative extent of tumor. 
Total dose and fractionation
Extremely heterogeneous fractionation schedules were employed in the literature. For the lower-dose volume, the majority of studies used a conventional fractionation [23, [27] [28] [29] 34 ], whereas some authors used a dose for fraction >2 and ≤3 Gy [22, 30, 32, 33] and only a study [7] , besides the current one, opted for fraction size >3 Gy. For the SIB volume, some authors chose a moderate hypofractionation (2.4-3 Gy per fraction) [23, [27] [28] [29] 34 ], whereas other authors tested a hypofractionation with doses for fraction ≥4 Gy, as in the current study [7, 22, 30, 32, 33] . Biologically effective dose and outcome
In Table 3 , the biologically effective dose (BED) relative to the different radiation schedules is shown. The BED was calculated according to the following formula where D = total dose, d = dose per fraction, α/β = α/β ratio. The BED for an alpha/beta ratio of 10 Gy of the standard treatment for glioblastoma (i.e. 60 Gy in 30 fractions) is 72 Gy. BED of the schedules employed in the existing literature series ranged between 74.4 [29, 32] and 125.8 Gy [7] for the SIB volumes and between 39 [22, [30] [31] [32] [33] and 67.2 Gy [34] for the lower-dose volumes.
In the current study, the choice of the fractionation to use had a rationale: BED for the SIB volume was 97.8 Gy for the SIB volume, relying on the results of Iuchi et al. [7] who stated that a BED ≥ 96 Gy in the boost volume was related to a better OS and PFS. On the other hand, BED for the lower-dose volume was 70.8 Gy in order to have a BED similar to the standard treatment.
Results in terms of efficacy of the existing studies in literature are very heterogeneous (Table 3) . Overall survival at 12 months of patients treated with such an approach ranged between 40% [23] and 78.7% [29] , while PFS at 12 months ranged between 25% [34] and 71.4% [7] . Actuarial OS and PFS of patients enrolled in the current study were 65.6 and 41.2%, respectively.
We did not find any statistically significant correlation between the BED and the outcome, either in terms of OS or PFS.
Toxicity
The outcome in terms of toxicity reported in literature varied widely as well. In the long-term follow-up, the rate of radionecrosis ranged between 0% [23, 27, 34] and 50% [31] . In the current series, only a case of radionecrosis (4.2%) was observed.
To our knowledge, this is the first study that reported the dose constraints adopted for the hypofractionated schedule. They came from the conversion of the constraints commonly used in conventionally fractionated radiotherapy, through the linear quadratic model (Table 2) . Despite the limited number of the patients enrolled in the present trial, it seems interesting that no late toxicity occurred to the organs at risk for which dose constraints had been set.
Addition of TMZ
The most recent trials added TMZ to the hypofractionated schedules [27] [28] [29] [30] [31] [32] . Interestingly, from literature data the
addition of concomitant and sequential chemotherapy seems to have a slight but significant impact on OS, although toxicity might increase, mainly in terms of myelotoxicity.
Prognostic factors
In the present series, only the MGMT promoter status was found to be related to OS. This factor was significant also in other two studies where patients were treated with temozolomide [27, 35] . Age [23, 28] , KPS [23, 28, 33] , RPA class [23, 27, 28] , extent of surgery [7, 23, 27, 30] , and multifocality [33] resulted to have an impact on prognosis in patients with glioblastoma treated with SIB technique in other literature studies but not in the present series, maybe due to the limited number of patients.
Advantages and pitfalls of the study
This study is a rare phase II trial evaluating the role of SIB in GBM but it is limited by a small number of patients, although, to our knowledge, the maximum number of patients ever included in a prospective series assessing the role of SIB in GBM is 40 [28, 29] . The difficulties encountered in the accrual of patients were mainly due to the maximum size of the preoperative lesion according to the eligibility criteria (≤4 cm as maximum diameter): this excluded many cases, otherwise eligible, from the enrollment.
Another limitation of the study is that patients were favorably selected because only patients belonging to III and IV RPA classes were enrolled.
To our knowledge, this is the first study to report primary and secondary dose constraints for all the organs at risk: they were derived from the constraints commonly used in conventional fractionation, by basing on the linear quadratic model. The low rate of the observed severe late toxicity related to radiotherapy in our series, in spite of the high BED of the chosen schedule and the use of temozolomide as a radiosensitizer, might highlight the importance to define and meet dose constraints.
Lastly, this series confirms that concomitant and sequential temozolomide is feasible also in hypofractionated schedules.
Conclusions
The hypofractionated schedule with SIB employed in this trial had comparable results in terms of efficacy with other studies in literature that used a SIB. The severe toxicity rate was limited in spite of the high BED of the chosen schedule and it might be due to the adoption of strict dose constraints.
